Asha Nayak, MD
Hematology & Oncology · Augusta, GANPI 1497864433
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,065 of the $5,032 with a category attached, or 80.8%. AstraZeneca accounts for 79.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $2,772 and has fallen 76.8% since, to $644 in 2025. That places this record below the midpoint for hematology & oncology clinicians in GA, where the typical reported total is $4,479.
Across 16 payments — averaging $314.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Sanofi$350
- Cardinal Health 110 LLC$275
- Amgen$173
- Ipsen Biopharmaceuticals, Inc$115
- Astellas Pharma US Inc$52
- plus $77 from 3 others
Across 45 payments — averaging $27,635 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1M
- Kyowa Kirin Pharmaceutical Development, Inc$168K
- G1 Therapeutics, Inc.$32K
- Alkermes, Inc.$20K
- AstraZeneca$3K
- Astrazeneca UK Limited$899
What the payments were for
- Consulting fees$4,06581%
- Speaking & faculty fees$55011%
- Food & beverage$2615%
- Education$1563%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 4 | $3,990 |
| Sanofi | 1 | $350 |
| Cardinal Health 110 LLC | 1 | $275 |
| Amgen | 3 | $173 |
| Ipsen Biopharmaceuticals, Inc | 1 | $115 |
| Astellas Pharma US Inc | 3 | $52 |
| Tesaro, Inc. | 1 | $37 |
| Merck | 1 | $20 |
| Caris MPI, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$1,050
- CAPRELSA$350
- SOMATULINE DEPOT$115
How this compares
$5,032 in reported general payments places this provider in the 50th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 17 | $54,392 |
| EliquisApixaban | 25 | $15,172 |
| Oxycodone Hcl | 124 | $5,802 |
| Imatinib Mesylate | 33 | $4,237 |
| Fentanyl | 11 | $1,072 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $1,005 |
| Ondansetron Hcl | 46 | $908 |
| Prochlorperazine Maleate | 25 | $867 |
| Morphine Sulfate ErMorphine Sulfate | 20 | $703 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $427 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $170 |
| Pantoprazole Sodium | 14 | $105 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Augusta
- Jigarkumar ParikhAugusta$267K
- Abdullah KutlarAugusta$196K
- Vamsi KotaAugusta$91K
- Girindra RavalAugusta$88K
- Brent LimbaughAugusta$72K
- Amany KeruakousAugusta$36K
- Eugene LongAugusta$34K
- David SquiresAugusta$33K
- Miriam AtkinsAugusta$28K
- Priya RudolphAthens$745K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.